# Tocilizumab in Coronavirus-19 Positive Patients

> **NCT04423042** · PHASE3 · UNKNOWN · sponsor: **University of Calgary** · enrollment: 30 (estimated)

## Conditions studied

- Covid19
- COVID-19
- Severe Acute Respiratory Syndrome Coronavirus 2
- Coronavirus
- Inflammation

## Interventions

- **BIOLOGICAL:** Tocilizumab

## Key facts

- **NCT ID:** NCT04423042
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-30
- **Primary completion:** 2021-06
- **Final completion:** 2021-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04423042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04423042, "Tocilizumab in Coronavirus-19 Positive Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04423042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*